Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine (Tan, et al, 2025)
Evidence suggests that "IV racemic ketamine is more effective than IN esketamine in TRD; convergent preclinical and clinical findings support the hypothesis that arketamine plays a key role in this superiority and that ketamine’s antidepressant mechanisms extend beyond simple NMDAR antagonism."

